- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.09. | Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 85 | GlobeNewswire (Europe) | MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 16.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 08.09. | Pasithea advances to second dose cohort in NF1 clinical trial | 4 | Investing.com | ||
| 08.09. | Pasithea: NF1-Studie erreicht nach positiver Sicherheitsprüfung die nächste Dosierungsstufe | 1 | Investing.com Deutsch | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.09. | Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 119 | GlobeNewswire (Europe) | -- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 03.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 31.07. | Pasithea completes enrollment of first cohort in NF1 clinical trial | 7 | Investing.com | ||
| 31.07. | Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 416 | GlobeNewswire (Europe) | MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 11.07. | Pasithea Therapeutics terminiert Hauptversammlung für den 3. September 2025 | 2 | Investing.com Deutsch | ||
| 11.07. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Pasithea Therapeutics Corp. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
| 02.06. | Pasithea reports promising phase 1 results for cancer drug | 2 | Investing.com | ||
| 02.06. | Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 | 264 | GlobeNewswire (Europe) | -- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated... ► Artikel lesen | |
| 20.05. | Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model | - | RTTNews | ||
| 20.05. | Pasithea's PAS-004 shows promise in inflammatory disease study | 1 | Investing.com | ||
| 20.05. | PAS-004 von Pasithea zeigt vielversprechende Ergebnisse in Studie zu Entzündungskrankheiten | 1 | Investing.com Deutsch | ||
| 20.05. | Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,380 | -5,99 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Ryan Confer, President and Chief Executive Officer of Genprex, Inc., to Present at Investor Summit Virtual on September 16, 2025 | AUSTIN, TX / ACCESS Newswire / September 10, 2025 / Genprex, Inc.'s President and Chief Executive Officer, Ryan Confer, will present at the Investor Summit Virtual on September 16, 2025, offering investors... ► Artikel lesen | |
| QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| BIONTECH | 88,40 | +0,63 % | Krebsforschung mit Milliarden-Potenzial: So könnten Bayer, Vidac Pharma und BioNTech ins Spiel kommen | Der Onkologie-Markt brummt wie kaum ein anderer. Getrieben von technologischen Quantensprüngen und leider auch steigenden Fallzahlen, entwickelt sich die Krebsbehandlung zum lukrativen Innovationsmotor.... ► Artikel lesen | |
| EVOTEC | 6,786 | +1,31 % | BioNxt Solutions, Bayer, Evotec - Enormes Upside! Schnittstelle von Biotech und Pharma! | Die weltweite Zunahme von Wohlstandserkrankungen wie Diabetes, Adipositas, Multipler Sklerose (MS) und MASH (metabolisch bedingte Fettleber) sorgt für ein enormes Wachstum im Gesundheitssektor. Ebenso... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,525 | 0,00 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| SUMMIT THERAPEUTICS | 22,945 | 0,00 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| MINERALYS THERAPEUTICS | 43,050 | 0,00 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| KYMERA THERAPEUTICS | 59,92 | +4,65 % | Stifel bestätigt Kaufempfehlung für Kymera Therapeutics vor wichtigen Studiendaten | ||
| BEAM THERAPEUTICS | 25,390 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| LENZ THERAPEUTICS | 38,610 | -0,34 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| ADMA BIOLOGICS | 14,550 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 20,900 | -1,09 % | Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' | ||
| ARVINAS | 9,800 | +3,70 % | Arvinas Inc.: Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress | ||
| GUBRA | 54,40 | -4,98 % | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Cro Gubra On Preclinical Trials Of Xen-d0501 In Obesity | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen |
PASITHEA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,744 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.